Effect of Ca2+ Ionophore on Embryonic Development and Clinical Outcome in Cases With Previous Fertilization Arrest
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02683031|
Recruitment Status : Unknown
Verified August 2016 by Yasmin Magdi, Dar AlMaraa Center.
Recruitment status was: Recruiting
First Posted : February 17, 2016
Last Update Posted : August 18, 2016
|Condition or disease||Intervention/treatment||Phase|
|Fertilization Arrest||Other: Ca2+ ionophore||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||50 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Prospective Randomized Controlled Trial Investigating Embryonic Development and Clinical Outcome After Using Ca2+ Ionophore in Cases With Previous Fertilization Arrest|
|Study Start Date :||May 2014|
|Estimated Primary Completion Date :||December 2017|
|Estimated Study Completion Date :||December 2017|
No Intervention: Without Ca2+ ionophore
Patients with previous incomplete ICSI cycle due to fertilization arrest were counseled to underwent a subsequent conventional ICSI cycle.
Experimental: With Ca2+ ionophore
Patients with previous incomplete ICSI cycle due to fertilization arrest were counseled to underwent a subsequent ICSI cycle combined with artificial oocyte activation using Ca2+ ionophore.
Other: Ca2+ ionophore
Ca2+ ionophore is a chemical agent used to perform oocyte activation after ICSI. It showed effective treatment to get better fertilization, pregnancy, and healthy livebirth in cases with total or partial fertilization failure.
Other Name: A23187 Ca2+ ionophore
- Blastocyst formation rate [ Time Frame: 5 to 7days post oocyte retrival ]Defined as the total number of blastocyst / total number of cleaved Embryos
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02683031
|Contact: Yasmin Magdi, M.Sc||+201282313979||Yas.email@example.com|
|Contact: Ahmed El-Damen, M.Sc||+201002414342||Ahmed_eldamen@Yahoo.com|
|Contact: Ahmed El-Damen|
|Principal Investigator:||Yasmin Magdi, M.Sc||Dar Almaraa fertility and gynacology center|
|Study Chair:||Mona M. Awady, MD||Department of Community Medicine, Faculty of Medicine, Benha University, Benha, Egypt|